PET Biomarkers in Treatment Resistant Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MAO-B Occupancy in Depressed Patients

NCT04841798

Major Depressive Disorder Treatment Resistant Depression

COMPLETED NA

PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder

NCT06452290

Major Depressive Disorder

NOT_YET_RECRUITING NA

Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer

NCT02153281

Major Depressive Disorder

COMPLETED NA

Characterizing Dopamine Receptor Binding in Treatment Resistant Depression

NCT03537794

Treatment Resistant Depression

NOT_YET_RECRUITING

DPA-714 and FDG PET/MRI in Depression

NCT06565936

Depression

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

While Major Depressive Disorder (MDD) is prevalent and disabling, compelling recent data from the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study indicate that only about half of patients attain remission from MDD, even after multiple antidepressant medication trials. Further, no biomarker has been validated which can select an effective treatment for such patients, presenting critical unmet intellectual and clinical challenges. The recent landmark finding of an markedly elevated level of monoamine oxidase A (MAO-A) in the brains of depressed patients with MDD compared to controls, using positron emission tomography (PET) with a positron-emitting carbon isotope, (carbon 11 \[11C\]) labeled monoamine oxidase inhibitor (MAOI), has provided an unparalleled opportunity to address these challenges. It has long been known that MAOIs are effective for some patients with treatment-resistant MDD, although their side effect profile makes them highly unacceptable both to patients and physicians, severely curtailing their utility.

This study seeks to: 1) replicate this study using PET scans in 20 subjects with MDD but extending it to patients with treatment-resistant depression (TRD). (Results from these participants with be compared to those from 10 non-depressed controls; 2) explore the correlation of the brain MAO-A level biomarker to treatment outcome by treating the 20 PET-imaged TRD patients with an MAOI, hypothesizing that their MAOI response will be related to their level of MAO-A. Brain MAO-A is an ideal candidate biomarker for this study since it appears to be significantly abnormally elevated in MDD, yet it has a broad range of values even among depressed patients. Most importantly, the MAO-A biomarker is known to be the single pharmacologic target of the treatment, making it appear likely that outcome with MAOI treatment will be related to MAO-A.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tranylcypromine

patients will receive treatment with tranylcypromine

Group Type OTHER

tranylcypromine

Intervention Type DRUG

MAO-Inhibitor 60mg-120mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tranylcypromine

MAO-Inhibitor 60mg-120mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Parnate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Primary diagnosis of Major Depressive Disorder
2. Subjects aged 18-65
3. Depressed subjects must have Treatment-Resistant Depression (TRD) two previous adequate antidepressant treatment trial failures within the current depressive episode from different classes
4. Minimum baseline Montgomery Asberg Depression Rating Scale (MADRS) score of 22
5. Signs informed consent form
6. Subjects must be willing to be have a PET scan
7. Subjects must be antidepressant medication free for 3 weeks prior to PET scan

EXCLUSION

1. Significant past or present neurological disorder, including seizures, stroke, or head trauma
2. History of bipolar disorder, psychosis, schizoaffective disorder, or schizophrenia
3. Moderate or high level of suicide risk, as determined by a score of 3 or 4 on item 3 of the HAM-D scale. Also excluded will be those who present a significant suicide risk by history or current psychiatrist's assessment.
4. Personality disorder which might interfere with compliance or increase suicide risk
5. Alcohol or drug abuse or dependence in the past year; history of lifetime IV drug use or use of methylene diamine methamphetamine (MDMA or "ecstasy") more than twice
6. Current thyroid dysfunction (past or currently treated dysfunction is acceptable)
7. Clinically significant or unstable medical conditions or laboratory abnormalities, including hypertension (repeated BP \> 140 systolic, \> 90 diastolic)
8. Intake of investigational (unapproved) drug in the past 3 months
9. Electroconvulsive therapy (ECT) in three months prior to screening
10. Use of Vagal Nerve Stimulation (VNS)
11. Positive drug of abuse screen
12. Anticoagulant treatment which cannot be discontinued for 10 days prior to PET scanning
13. Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.
14. Dementia (clinical and neurocognitive criteria)
15. Claustrophobia of a severity which would not permit the participant to undergo an MRI or a PET scan
16. Recent (\< 7 days) consumption of Ayahuasca Tea or other South American non-standard decoction.
17. Presence of metallic devices, implants and other contraindications to scanning
18. Current, past or anticipated exposure to radiation, that may include being badged for radiation exposure in the workplace or participation in nuclear medicine research protocols
19. Smokers (use of tobacco products in the previous 3 months)
20. Potential participants having taken an antidepressant medication in the last 3 weeks. Participants otherwise eligible may elect to discontinue medication which has not been significantly helpful according to their report, their current psychiatrist's report (if available), and the evaluating psychiatrist. No patient will be asked to discontinue an effective antidepressant medication to participate.
21. History of previous MAO-I treatment

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes